IL2 and type 1 diabetes mellitus: A major caveat, however, is finding a dose regimen of IL-2 that only affects Tregs and does not activate CD8+ T cells and NK cells in parallel, as recently observed in a clinical trial of low dose IL-2 and rapamycin in T1D (71, 72).